Skip to main content
. Author manuscript; available in PMC: 2021 Oct 1.
Published in final edited form as: JACC Heart Fail. 2020 Aug 12;8(10):834–843. doi: 10.1016/j.jchf.2020.06.008

Figure 4. Change in NT-proBNP concentration over time among patients who remained at dose level 1 of blinded study drug at 4 weeks post-randomization.

Figure 4.

The reduction in NTproBNP concentration with sacubitril/valsartan vs. enalapril was consistent in patients who remained on dose level 1 of blinded study drug at 4 weeks post-randomization. The model is adjusted for age, systolic blood pressure, and race. NT-proBNP, N-terminal pro-B-type natriuretic peptide.